The sacroiliac joint is a common source of chronic lower back pain and a novel RFA-based approach to sacroiliac joint denervation may provide intermediate-term pain relief and functional benefit ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the Tenon Medical Third Quarter 2024 ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

Needham analyst David Saxon reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $19.00. David ...

Analyst Drew Ranieri from Morgan Stanley maintained a Buy rating on SI-Bone (SIBN – Research Report) and keeping the price target at ...

Nevro Corp. , a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Q Revenue of $0.9 Million, Consistent with Prior Quarter; Year to Date Revenue of $2.5 Million, Growth of 18.3% Compared to Prior Year ~~ Published Interim Analysis from MAINSAIL Study; Post-Market ...

The findings mark a new era in joint pain management, and as researchers delve deeper into the effects of this medication, its potential to transform the landscape of osteoarthritis treatment ...

Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.